- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Celldex Therapeutics Inc (CLDX)
Track today's live Celldex Therapeutics (CLDX) share price, performance and key data on this page with our current NASDAQ:CLDX stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Celldex Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the CLDX share price, head to our technical summary section, which provides analysis on Celldex Therapeutics share price buy/sell indicators using real-time data (or discuss the Celldex Therapeutics (CLDX) stock price today with other investors in the Celldex Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CLDX share price (ISIN: US15117B2025) to enhance your trading decisions with our free investment tools and resources.
What Is the Celldex Therapeutics Inc Share Price Today?
The Celldex Therapeutics share price today is 35.42.
What Is the Stock Symbol for Celldex Therapeutics Inc
The stock symbol (or 'ticker') for Celldex Therapeutics Inc is "CLDX."
What Stock Exchange Does Celldex Therapeutics Inc Trade On?
Celldex Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Celldex Therapeutics Inc a Good Stock to Buy?
Determining whether Celldex Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CLDX share price (ISIN: US15117B2025) to enhance your trading decisions with our free investment tools and resources.
What Is the Celldex Therapeutics Inc Share Price Today?
The Celldex Therapeutics share price today is 35.42.
What Is the Stock Symbol for Celldex Therapeutics Inc
The stock symbol (or 'ticker') for Celldex Therapeutics Inc is "CLDX."
What Stock Exchange Does Celldex Therapeutics Inc Trade On?
Celldex Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Celldex Therapeutics Inc a Good Stock to Buy?
Determining whether Celldex Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
35.29
36.65
52 wk Range
19.72
40.30
CLDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
35.2936.65
52 wk Range
19.7240.30
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLDX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
57.53
Upside
+62.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
- Form 4 Celldex Therapeutics Inc For: 29 June
- Investing.com
- Celldex CFO Sam Martin to retire in March 2027
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
15 Buy
1 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 57.53
(+62.43% Upside)
Celldex Therapeutics Inc SWOT Analysis
Barzolvolimab's Promise | Explore barzolvolimab's potential in chronic spontaneous urticaria, with a 41% complete response rate at 150 mg Q4W dose, despite setbacks in eosinophilic esophagitis trials |
Market Opportunities | Delve into the significant CSU market, with analysts projecting potential peak sales of $1 billion for barzolvolimab, despite challenges in the competitive landscape |
Financial Health | Learn about Celldex's robust financial position, with $673 million in cash and a strong Altman Z-Score of 20.23, providing runway through 2027 for continued development |
Analyst Outlook | Discover analyst consensus with a strong buy recommendation and price targets ranging from $30 to $90, suggesting significant potential upside from current levels |
Earnings
Latest Release
07/05/2026
EPS / Forecast
-1.18 / -1.19
Revenue / Forecast
15K / 874.9K
Compare CLDX to Peers and Sector
Metrics to compare | CLDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.8x | −1.3x | −0.4x | |
PEG Ratio | 0.17 | −0.05 | 0.00 | |
Price/Book | 6.1x | 2.2x | 2.6x | |
Price / LTM Sales | 3,207.7x | 12.1x | 3.0x | |
Upside (Analyst Target) | 52.8% | 395.9% | 53.2% | |
Fair Value Upside | Unlock | 11.3% | 9.0% | Unlock |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Celldex Therapeutics (NASDAQ: CLDX) Share Price Today?
The Celldex Therapeutics stock price today is 35.42 USD.
What Stock Exchange Does Celldex Therapeutics (CLDX) Trade On?
Celldex Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Celldex Therapeutics?
The stock symbol (also called a 'ticker') for Celldex Therapeutics is "CLDX."
What Is the Current Celldex Therapeutics Market Capitalisation?
As of today, Celldex Therapeutics (NASDAQ: CLDX) market cap is 2.78B USD.
What Is Celldex Therapeutics's (CLDX) Earnings Per Share (TTM)?
The Celldex Therapeutics EPS is currently -4.27 (Trailing Twelve Months).
When Is the Next Celldex Therapeutics Earnings Date?
Celldex Therapeutics's next earnings report will be released on 06/08/2026.
Is CLDX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Celldex Therapeutics moving averages and other technical indicators, the daily buy/sell signal for CLDX stock is Sell.
How Many Times Has Celldex Therapeutics Stock Split?
Celldex Therapeutics has split 2 times. (See the CLDX stock split history page for full effective split date and price information.)
How Many Employees Does Celldex Therapeutics Have?
Celldex Therapeutics has 198 employees, based on their latest Companies House report.
What is the current trading status of Celldex Therapeutics (NASDAQ: CLDX)?
As of 20/07/2026, Celldex Therapeutics (CLDX) is trading at a share price of 35.42 USD, with a previous close of 35.35 USD. The stock has fluctuated within a day range of 35.29 USD to 36.65 USD, while its 52-week range spans from 19.72 USD to 40.30 USD.
What Is Celldex Therapeutics (CLDX) Price Target According to Analysts?
The average 12-month price target for Celldex Therapeutics is 57.53 USD, with a high estimate of 90 USD and a low estimate of 38 USD. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +62.43% Upside potential.
What Is the CLDX Premarket Price?
CLDX's last pre-market stock price is 35.80 USD. The pre-market share volume is 1,240.00, and the stock has decreased by 0.45, or 1.27%.
What Is the CLDX After Hours Price?
CLDX's last after hours stock price is 34.74 USD, the stock has decreased by -0.68, or -1.93%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.